# Dapagliflozin Effect in Cognitive Impairment in Stroke Trial

> **NCT05565976** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Jaime Daniel Mondragon** · enrollment: 270 (estimated)

## Conditions studied

- Stroke, Ischemic
- Mild Cognitive Impairment
- Dementia, Vascular
- Metabolic Syndrome

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab
- **DRUG:** Statins (Cardiovascular Agents)
- **DRUG:** Platelet Antiaggregant
- **DRUG:** Antidiabetic

## Key facts

- **NCT ID:** NCT05565976
- **Lead sponsor:** Jaime Daniel Mondragon
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-07-01
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2022-10-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05565976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05565976, "Dapagliflozin Effect in Cognitive Impairment in Stroke Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05565976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*